By Lina carolina 
Cancer immunotherapy has revolutionized the treatment landscape for numerous malignancies, offering new hope and significantly improving patient outcomes. However, pancreatic cancer has persistently remained a formidable challenge, largely impervious to these groundbreaking advancements. A primary impediment lies in the unique and hostile tumor microenvironment that pancreatic tumors cultivate, often described as "cold," effectively shielding them from immune cell infiltration and the subsequent immune attack. Now, a pioneering approach developed by researchers at the University of Chicago is poised to potentially dismantle this barrier and usher in a new era of pancreatic cancer treatment.
A Novel Approach to Combatting Pancreatic Cancer’s Defenses
In a significant stride forward, a team at the University of Chicago has engineered a novel therapeutic strategy utilizing BifidoSumIL-2, a specially modified strain of Bifidobacterium longum. This probiotic bacterium, commonly found in the human gut, has been repurposed to act as a targeted delivery system, transporting an immune-stimulating payload directly into pancreatic tumors. The findings, published in the esteemed journal Science Advances, detail how this innovative therapy demonstrated a marked reduction in tumor growth in preclinical animal models by selectively invigorating cancer-fighting T cells. Crucially, the efficacy of BifidoSumIL-2 was amplified when administered in conjunction with established cancer treatments such as chemotherapy, radiotherapy, and conventional immunotherapy, suggesting a powerful synergistic potential. This research offers a compelling glimpse into a future where pancreatic tumors could become far more responsive to treatment.
The "Bugs as Drugs" Revolution: Harnessing Bacteria for Therapeutic Delivery
The quest to conquer pancreatic cancer, a disease with notoriously poor prognoses and a significant unmet medical need, has been a central focus for oncologists and researchers worldwide. Dr. Ralph Weichselbaum, the Daniel K. Ludwig Distinguished Service Professor and Chair of Radiation and Cellular Oncology at the University of Chicago, articulated the gravity of this challenge: "A big unmet medical need has been pancreatic cancer, and so that was going to be our mountain to climb."
The BifidoSumIL-2 system is designed to release a precisely engineered version of interleukin-2 (IL-2) upon reaching its tumorous destination. IL-2 is a potent cytokine that plays a critical role in activating T cells, the immune system’s frontline soldiers against cancer. However, traditional IL-2 therapies have been plagued by significant drawbacks, including severe systemic side effects and the unintended stimulation of regulatory T cells, which can paradoxically suppress anti-tumor immune responses.
To circumvent these limitations, the University of Chicago team developed SumIL-2, a modified IL-2 molecule engineered for enhanced specificity. SumIL-2 is designed to more potently activate cancer-fighting T cells while minimizing the activation of immunosuppressive regulatory T cells. The true innovation lies in encapsulating SumIL-2 within Bifidobacterium longum. This strategic packaging ensures that the therapeutic agent is concentrated within the tumor site, rather than circulating throughout the entire body, thereby maximizing local impact and minimizing off-target effects.
This ambitious project necessitated a highly interdisciplinary collaboration, bringing together expertise from microbiology, synthetic biology, oncology, and immunology. "This was a highly interdisciplinary effort," stated Dr. Mark Mimee, Assistant Professor of Microbiology at the University of Chicago. "We had to bring together people who understand bacteria, people who understand tumors, and people who understand the immune system to make something like this possible." This synergy of diverse scientific disciplines underscores the complexity and innovation inherent in developing such advanced therapeutic modalities.
Exploiting Tumor Microenvironments: Why Bifidobacterium is an Ideal Trojan Horse
The choice of Bifidobacterium as a delivery vehicle was not arbitrary; it offered a unique biological advantage. This bacterium thrives in anaerobic environments – areas with very little oxygen. Such low-oxygen conditions are a hallmark of many solid tumors, including pancreatic tumors, whereas healthy tissues generally maintain higher oxygen levels, making them less hospitable for Bifidobacterium.
Dr. Mimee elaborated on this crucial characteristic: "Bifidobacterium is an obligate anaerobe, so it doesn’t grow in the presence of oxygen. When the bacteria are injected systemically, they are cleared from healthy tissues with abundant oxygen. Inside the low-oxygen regions of tumors, however, they can become active." This inherent preference allows the engineered bacteria to function as sophisticated, microscopic drug factories precisely within the tumor. Once localized, they meticulously produce SumIL-2 at the site of greatest need, avoiding widespread systemic exposure.
Furthermore, Bifidobacterium boasts a favorable safety profile, with a history of successful use as a probiotic. It is commonly found in foods like yogurt and is generally recognized as safe (GRAS) by regulatory bodies. This established safety record significantly de-risks the development of a bacterial-based therapy.
However, engineering this beneficial bacterium was not without its challenges. "Bifidobacterium is not the easiest organism to work with," Dr. Mimee admitted. "It’s anaerobic, it grows slowly, and the genetic tools for manipulating it are much more limited compared to model bacteria like E. coli. A lot of the work was just figuring out how to reliably engineer it." The successful manipulation of Bifidobacterium‘s genetic machinery to produce and deliver the therapeutic payload represents a significant technical achievement.
Synergy in Action: Amplified Efficacy with Combination Therapies
In extensive testing within animal models, BifidoSumIL-2 demonstrated its ability to accumulate preferentially within tumors, effectively stimulate immune activity, and consequently slow the progression of pancreatic cancer. Beyond direct immune activation, the therapy also began to reshape the tumor microenvironment in a manner conducive to anti-cancer immunity, notably by increasing the presence and activity of cancer-fighting CD8+ T cells.
The most striking findings emerged when BifidoSumIL-2 was integrated into existing treatment regimens. Combining the bacterial therapy with chemotherapy, radiation therapy, or the immunotherapy drug anti-PD-L1 resulted in significantly superior tumor control and extended survival rates compared to any of the individual treatments. "This combination potential is one of the study’s most important findings; BifidoSumIL-2 not only works by itself — it works with radiotherapy, chemotherapy, and immunotherapy," emphasized Dr. Weichselbaum. This synergistic effect suggests that BifidoSumIL-2 could act as an immune-priming agent, making tumors more susceptible to conventional therapies.
Future Directions and the Expanding "Bugs as Drugs" Paradigm
Despite the highly encouraging preclinical results, BifidoSumIL-2 is yet to undergo human trials. Extensive future research will be crucial to evaluate its long-term safety profile, investigate potential off-target effects beyond the intended tumor, assess the durability of the induced immune response, and explore the feasibility of oral administration as an alternative to injection. The research team also intends to investigate the compatibility of this strategy with emerging pancreatic cancer treatments, including novel KRAS inhibitors, which target a common genetic mutation found in pancreatic cancers.
This groundbreaking work contributes to the burgeoning field of "bugs as drugs." By genetically engineering probiotic bacteria to actively seek out and colonize tumors, and subsequently produce therapeutic agents directly within these sites, scientists aim to concentrate potent treatments where they are most needed. This approach holds the promise of enhancing therapeutic efficacy while simultaneously minimizing the debilitating side effects often associated with systemic drug administration.
The study, titled "Engineered probiotic Bifidobacterium for tumor-targeted pancreatic cancer therapy," received vital support from the Ludwig Foundation and the National Institutes of Health, underscoring the significant investment in this promising area of research. The research team also included Jaehyun Lee, Kaiting Yang, Christina Nowicki, Wei Liu, Emile Naccasha, and Hua Liang from the University of Chicago; Zhichen Sun from the University of Texas Southwestern, Dallas; and Yang-Xin Fu from Tsinghua University, Beijing, China.
The University of Chicago Medicine and its Biological Sciences Division remain at the vanguard of cancer care and research. In a testament to their commitment to advancing patient care, UChicago Medicine will open the AbbVie Foundation Cancer Pavilion in April 2027. This state-of-the-art facility will be Chicago’s first freestanding cancer pavilion, dedicated to providing cutting-edge diagnostics, pioneering treatments, accelerating translational discoveries, and offering comprehensive support services to patients and the wider community, further solidifying the institution’s role in shaping the future of cancer therapy.
